Breaking News

Theradaptive Awarded $4M DOD Contract for OsteoAdapt Regenerative Therapeutic Program

The contract will fund the company’s OsteoAdapt regenerative therapeutic product for spine and trauma repair to first in human clinical studies.

Theradaptive, a biotechnology company specializing in therapeutic delivery platforms, received a Technology & Therapeutic Development Award (TTDA) of $4 million from the U.S. Department of Defense (DOD) through the Peer Reviewed Medical Research Program (PRMRP) of the Congressionally Directed Medical Research Programs (CDMRP). The contract will fund the company’s OsteoAdapt regenerative therapeutic product for spine and trauma repair to first in human clinical studies. “This awar...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters